Clinical Trials
23 trialsNCT04960709 2026-06-04
VOLGA
AstraZeneca
Phase 3 Active not recruiting
NCT04739800 2026-05-29
Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03682068 2026-05-28
NILE
AstraZeneca
Phase 3 Active not recruiting
NCT05943106 2026-05-26
PATAPSCO
AstraZeneca
Phase 3 Active not recruiting
NCT04216290 2026-05-22
A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05043090 2026-05-22
SAMETA
AstraZeneca
Phase 3 Active not recruiting
NCT03459846 2026-05-11
BAYOU
AstraZeneca
Phase 2 Active not recruiting
NCT03601455 2026-05-11
Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer
Jonsson Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT05154994 2026-05-07
RESOLVE
University of Utah
Phase 1 Active not recruiting
NCT03682289 2026-04-23
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
University of California, San Francisco
Phase 2 Active not recruiting
NCT04521686 2026-04-22
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Phase 1 Active not recruiting
NCT02516241 2026-04-20
Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
AstraZeneca
Phase 3 Active not recruiting
NCT03528694 2026-04-14
POTOMAC
AstraZeneca
Phase 3 Active not recruiting
NCT03795207 2026-03-31
POSTCARD
Institut Cancerologie de l'Ouest
Phase 2 Active not recruiting
NCT04637594 2026-03-20
IMAGINE
Alliance for Clinical Trials in Oncology
Phase 3 Active not recruiting
NCT03732677 2026-03-13
NIAGARA
AstraZeneca
Phase 3 Active not recruiting
NCT05137262 2026-02-18
A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03768570 2026-02-02
Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer
Canadian Cancer Trials Group
Phase 2 Active not recruiting
NCT03228667 2026-01-14
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
ImmunityBio, Inc.
Phase 2 Active not recruiting
NCT02546661 2025-12-29
BISCAY
AstraZeneca
Phase 1 Active not recruiting
NCT03983954 2025-11-28
Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.
NeoTX Therapeutics Ltd.
Phase 1 Active not recruiting
NCT03385655 2025-08-21
Prostate Cancer Biomarker Enrichment and Treatment Selection
Canadian Cancer Trials Group
Phase 2 Active not recruiting
NCT03308396 2022-02-17
Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer
Big Ten Cancer Research Consortium
Phase 1/2 Active not recruiting